Previous close | 1,461.00 |
Open | 0.00 |
Bid | 0.00 x 0 |
Ask | 0.00 x 0 |
Day's range | 0.00 - 0.00 |
52-week range | |
Volume | |
Avg. volume | 10,464,897 |
Market cap | 60.831B |
Beta (5Y monthly) | 0.27 |
PE ratio (TTM) | 13.63 |
EPS (TTM) | 1.09 |
Earnings date | 26 Apr 2023 |
Forward dividend & yield | 0.61 (4.25%) |
Ex-dividend date | 23 Feb 2023 |
1y target est | N/A |
Charlie Carman examines a pair of healthcare shares he'll buy in February for passive income, thanks to their rock-solid dividend yields. The post 2 shares to buy in February for healthy dividends appeared first on The Motley Fool UK.
The Equity Index 2022/23 produced by Lead 5050 ranked firms using official data on average salaries, bonuses, and pay.
GSK announces the FDA approval of daprodustat for the treatment of anemia due to chronic kidney disease (CKD) in adults on dialysis for at least four months.